CQC-regulated clinics & online consultations
Posted on August 19, 2024 by Sally-Anne Turner
Like many healthcare professionals across the United Kingdom, at Bodyline our team have been shocked and deeply concerned when reading the latest reports on the widespread misuse of weight loss medications in the UK. As a CQC-regulated medical wellness clinic with over 18 years of experience in safe prescribing practices, we have witnessed firsthand the transformative power of properly supervised medical weight loss treatments. However, the recent surge in unregulated access to these powerful medications has created a public health crisis that demands urgent attention from healthcare providers, regulators, and patients alike.
In June 2024, the NHS medical director, Professor Stephen Powis gave a speech at the NHS Confederation conference that sent shockwaves through the medical community. He spoke candidly about being alarmed at reports that weight loss injections like WeGovy and Mounjaro are being misused by people in the UK looking for a quick fix for weight loss, often without proper medical supervision or genuine clinical need. His warnings highlighted a growing trend that medical professionals like our team at Bodyline have been observing with increasing concern over the past year.
The BBC reported that many online pharmacies are offering these injections to those willing to pay, with minimal checks on the medical history or eligibility of those willing to buy them. These platforms often use simple tick-box questionnaires that can be easily manipulated, bypassing the thorough medical assessments that should be mandatory before prescribing such powerful medications. As a result, people who simply want to lose a few pounds—individuals who may not even be overweight, let alone obese—are able to access prescription-only medications that were specifically developed and approved only for the treatment of obesity under proper medical supervision. This represents a fundamental misunderstanding of what these medications are designed to do and who they are designed to help.
What's more concerning is the online 'black market' of beauticians and salons offering weight loss jabs via social media platforms like Instagram, Facebook, and TikTok. These unregulated providers have been readily reported as causing a number of serious health problems and adverse reactions, as the medications cannot be verified to contain the semaglutide or tirzepatide they are advertised to be. In some cases, investigations have revealed that these injections contain unknown substances, incorrect dosages, or have been stored improperly, rendering them potentially dangerous or ineffective. The individuals selling these products often have no medical training whatsoever and are motivated purely by profit, with no regard for patient safety or wellbeing.
Bodyline's team of practitioners and nurse prescribers are trained and experienced in providing bespoke medical wellness treatments, but we prioritise the safety and wellbeing of our patients above all else. Every member of our clinical team undergoes rigorous training in the safe prescribing of weight loss medications, understanding not just how these drugs work but also how to identify patients who may be at risk of adverse effects, how to monitor for complications, and how to provide the comprehensive lifestyle support that makes these treatments truly effective. Our status as Care Quality Commission (CQC) regulated ensures the safe running of our services and offers security for all our patients when they are a part of our care. This regulation means we are subject to regular inspections, must maintain detailed clinical records, and are held accountable to the highest standards of medical care in the United Kingdom.
This article aims to voice in-depth the dangers of unregulated online pharmacies and sellers when it comes to weight loss injections, with our experts at Bodyline explaining the health risks involved to patients when they are not using the medications as prescribed. We will explore the science behind how these medications work, who they are genuinely designed to help, what constitutes inappropriate use, and why proper medical supervision is not just recommended but absolutely essential for patient safety.
To fully explore the dangers of improper use of weight loss injections such as WeGovy and Mounjaro, it's important to explain how the medications work and how they are intended to be prescribed. Understanding the mechanism of action helps illuminate why these are powerful pharmaceutical interventions that require careful medical oversight, not simple dietary supplements that can be used casually without professional guidance.
WeGovy and Ozempic are both once-weekly injections produced by pharmaceutical and global healthcare company Novo Nordisk and contain the active ingredient semaglutide. These medications represent years of pharmaceutical research and clinical trials involving thousands of participants, designed specifically to address the complex biological mechanisms that make obesity such a challenging condition to treat through diet and exercise alone.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, mimicking a hormone produced in the gut following mealtimes, glucagon-like peptide-1 (GLP-1). This is not a stimulant or appetite suppressant in the traditional sense—it works by replicating and enhancing a natural biological process that occurs in healthy individuals after eating. The synthetic version used in these medications is modified to last much longer in the body than the natural hormone, providing sustained effects throughout the week between doses.
GLP-1 is released by the intestines in response to food intake, particularly carbohydrates. It has many purposes in our body; the main functions are regulating blood sugar levels, controlling appetite, and aiding in insulin production. When you eat a meal, GLP-1 is released from cells in your small intestine and travels through your bloodstream to various organs, including your pancreas, stomach, and brain. In the pancreas, it stimulates the release of insulin when blood sugar levels are elevated, helping to keep glucose levels stable. In the stomach, it slows gastric emptying—the rate at which food leaves your stomach and enters your intestines—which contributes to feelings of fullness and satisfaction after eating. In the brain, it acts on appetite centres to reduce hunger signals and food cravings.
It is a natural hormone that helps to slow down digestion, increase satiety, and reduce food intake, but people with obesity can be resistant to it or may not produce enough. This is similar to how people with type 2 diabetes can become resistant to insulin—the body's natural regulatory mechanisms become less effective over time, contributing to weight gain and making weight loss increasingly difficult. Some individuals may have genetic variations that affect GLP-1 production or receptor sensitivity, whilst others may develop resistance as a consequence of prolonged obesity and metabolic dysfunction.
Therefore, when we administer semaglutide, the body's ability to regulate blood sugar, control appetite, slow digestion, and aid in insulin production is boosted, encouraging weight loss. The medication essentially restores or enhances the natural biological processes that should be helping to regulate body weight but have become impaired. This is why semaglutide was approved by NICE to treat obesity in the UK for those with a BMI of above 35 or above 30 with weight-related health problems such as type 2 diabetes, high blood pressure, or cardiovascular disease.
As a result, users are able to lose up to 15% of their starting body weight when the medication is used alongside lifestyle changes such as reduced caloric intake and increased physical activity. This level of weight loss is clinically significant—it's associated with meaningful improvements in obesity-related health conditions, reduced risk of developing type 2 diabetes, improvements in cardiovascular health markers, and enhanced quality of life. However, it's crucial to understand that these impressive results were achieved in clinical trials where participants received comprehensive support, regular monitoring, and guidance on diet and exercise. The medication alone, without these supporting interventions, is far less effective and potentially more dangerous.
The difference between Ozempic and WeGovy lies in the dosage and intended use; Ozempic is approved for the treatment of type-2 diabetes and comes in lower dosages, while WeGovy is approved for the treatment of obesity and is produced in a series of higher dosages. Both medications contain the same active ingredient—semaglutide—but WeGovy was specifically studied and approved for weight management, with dosing protocols optimised for this purpose. Ozempic's approval is for diabetes management, where weight loss is considered a beneficial side effect rather than the primary therapeutic goal. Using Ozempic "off-label" for weight loss has become common, but this practice raises concerns about appropriate dosing and monitoring. Both are to be titrated from lower to higher across a period of time, typically starting at 0.25 mg per week and gradually increasing over 16-20 weeks to the maintenance dose of 2.4 mg for WeGovy. This gradual titration is not arbitrary—it allows the body to adjust to the medication's effects and significantly reduces the severity of side effects, particularly the gastrointestinal symptoms that are most common when starting treatment.
Mounjaro is one of the newest weight loss injectable therapies approved for the treatment of obesity and has been labelled the 'King Kong' of weight loss medications due to its unprecedented effectiveness in clinical trials. Manufactured by pharmaceutical company Eli Lilly, Mounjaro represents the next generation of weight loss medications, building on the success of GLP-1 agonists like semaglutide but with an enhanced mechanism of action that targets two hormone pathways simultaneously.
Its mechanism of action, tirzepatide, is dual-acting as it mimics two hormones therefore increasing the likelihood of weight loss. Alongside GLP-1, the once-weekly injection mimics gastric inhibitory polypeptide (GIP), which is also known as glucose-dependent insulinotropic polypeptide. GIP is another incretin hormone produced in the gut that works alongside GLP-1 to regulate blood sugar and metabolism. Like GLP-1, GIP stimulates insulin secretion in response to food intake, but it also has additional effects on fat metabolism and energy storage. By targeting two potential hormonal deficiencies or resistances, weight loss success has been unparalleled, and satiety, blood sugar levels, and reduction of food intake is really boosted.
The dual-action approach of tirzepatide appears to produce synergistic effects—the combined impact of activating both GLP-1 and GIP receptors is greater than the sum of activating each individually. This may be because the two hormones work through slightly different mechanisms and in different tissues, creating a more comprehensive metabolic effect. Some research suggests that GIP may enhance the effects of GLP-1 on appetite suppression and may have independent benefits for insulin sensitivity and fat metabolism.
Clinical trials reported participants saw an average 20% body weight reduction when paired with diet and exercise, and the medication was approved by the Medicines and Healthcare products Regulatory Agency (MHRA) late 2023 for treating obesity in those with BMIs of above 35 or above 30 with weight health problems. These results represent some of the most significant weight loss outcomes ever seen in pharmaceutical trials, approaching the level of weight loss typically only achieved through bariatric surgery. In the SURMOUNT clinical trial programme, some participants lost more than 25% of their starting body weight—truly transformational results for individuals who had struggled with obesity for years or decades.
Again, the injection is to be titrated, so is produced in several dosages, and is designed to be used alongside a supported programme of diet and exercise. The titration schedule for Mounjaro typically begins at 2.5mg per week, increasing every four weeks through 5mg, 7.5mg, 10mg, 12.5mg, and potentially up to 15mg depending on individual response and tolerance. This careful dose escalation is even more important with tirzepatide than with semaglutide, as the dual mechanism of action can produce more pronounced effects—both therapeutic and adverse. Patients who skip doses or attempt to increase their dose too quickly are at significantly higher risk of severe gastrointestinal side effects and other complications.
Now we know how the injections work for weight loss, how they have been approved to be prescribed, and who is eligible for them, I'm sure it's obvious we can work out who would be ineligible for these medications, and what use is inappropriate. The eligibility criteria established by NICE, the MHRA, and the pharmaceutical manufacturers are not arbitrary restrictions designed to limit access—they are evidence-based guidelines developed to ensure patient safety and optimal outcomes based on extensive clinical trial data.
However, based on the worrying numbers of people misusing the medications and ending up in hospital, maybe it's not as obvious as we think. Emergency department doctors across the UK are reporting increasing numbers of patients presenting with complications from weight loss medications, including severe dehydration, electrolyte imbalances, pancreatitis, gallbladder problems, and dangerous drops in blood sugar. Many of these patients obtained their medications through unregulated channels and were using them without proper medical supervision.
One example of inappropriate use would be to be ineligible for WeGovy or Mounjaro and still gain a prescription and use them. The eligibility criteria exist because the clinical trials that established these medications' safety and efficacy were conducted on specific patient populations—people with obesity or significant overweight with comorbidities. We simply don't have robust safety data for using these powerful medications in people who don't meet these criteria.
Those who are not eligible include people who do not have a BMI of obese, or do not suffer from weight related health problems such as high blood pressure, type 2 diabetes, high cholesterol, or sleep apnoea. If you have a BMI under 30 (or under 27 without weight-related health conditions), these medications are not appropriate for you. The risks of side effects do not outweigh the potential benefits when you don't have clinically significant excess weight to lose. Using these medications for cosmetic weight loss—to lose a few pounds to fit into a dress or look good for a holiday—is not only inappropriate but potentially dangerous.
Also, you would not be eligible if you have a contraindication in your medical history or are currently on medications that are not conducive with the injection. For instance, anyone who has suffered from an eating disorder in the past would be ineligible. Other contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, severe gastrointestinal disease, diabetic retinopathy, and pregnancy or breastfeeding. Certain medications can interact dangerously with GLP-1 agonists, including some diabetes medications, insulin, and drugs that slow gastric emptying. A thorough medical history and medication review is essential before prescribing these treatments.
Using faceless online pharmacies with simple tick boxes and forms can leave ineligible patients open to a number of dangers and risks. These platforms often rely on patients to self-report their medical history accurately and honestly, but there's no verification process, no access to medical records, and no clinical judgment being applied. Someone with an active eating disorder might tick "no" to that question because they don't recognise their condition or are in denial. Someone taking a contraindicated medication might not realise it's relevant. Someone might underestimate their cardiovascular risk factors or fail to mention a family history of thyroid cancer. These gaps in information can have serious, even life-threatening consequences.
Speaking to medical professionals who can provide accurate advice and guidance on eligibility before offering a prescription is absolutely vital for patient safety, however continued supervision and monitoring of the medication's effects is just as important. The initial assessment determines whether it's safe to start the medication, but ongoing monitoring ensures it remains safe and effective throughout treatment. Weight loss medications are not "set it and forget it" treatments—they require active medical management.
At Bodyline, we only provide medications to those who are eligible when they sign up to a fully supported medical weight loss programme that includes regular check ups, weigh ins, and support calls. Our patients are seen by a qualified nurse or doctor at regular intervals throughout their treatment journey. These appointments aren't just about weighing in—they're comprehensive consultations where we assess how the medication is working, monitor for side effects, check blood pressure and other vital signs, discuss any challenges or concerns, provide nutritional guidance, and adjust the treatment plan as needed. We also maintain detailed clinical records that allow us to track progress over time and identify any concerning patterns early.
It is incredibly alarming to us that individuals can access a month's worth of medication with absolutely no supervision or monitoring of the progress and impact that the drugs have on the patient. Without supervision, patients may experience severe side effects and be unsure whether that is wrong or expected and may not alter their dosage or stop taking the medication. For example, persistent vomiting and inability to keep down fluids can lead to dangerous dehydration and electrolyte imbalances, but someone without medical guidance might assume this is a normal part of the treatment and try to push through it. Similarly, severe abdominal pain could indicate pancreatitis—a serious complication requiring immediate medical attention—but without proper education about warning signs, a patient might dismiss it as ordinary stomach upset.
It essentially opens both the individuals and the seller up to a world of ethical problems. For the patient, lack of supervision increases the risk of serious adverse events, reduces the likelihood of achieving optimal results, and leaves them without support when challenges arise. For the prescriber (if they can even be called that), it represents a fundamental failure of medical ethics and duty of care. Prescribing powerful medications without proper assessment and follow-up is negligent practice that puts profit above patient welfare.
Another example of inappropriate usage is using the wrong dose. Titration is vital in the prescription of all weight loss injections, as it reduces the risk and severity of adverse effects and reactions. The carefully structured dose escalation schedules recommended by the manufacturers are based on extensive clinical trial data showing optimal balance between efficacy and tolerability. Starting at too high a dose dramatically increases the likelihood of severe side effects that may cause patients to discontinue treatment prematurely.
For example, gastrointestinal issues such as nausea and diarrhoea will be less severe and easier to get over when a patient begins on a lower dose and increases gradually over time. Side effects must be monitored regularly to ensure the patient is not in danger. Most patients experience some degree of nausea when starting GLP-1 medications, but with proper titration, this is usually mild and resolves within a few days to weeks as the body adjusts. However, starting at a high dose can cause severe, persistent nausea and vomiting that leads to dehydration, inability to take in adequate nutrition, and significant distress. Some patients who obtain medications through unregulated sources may start at maintenance doses (like 2.4mg of semaglutide) without the gradual build-up, resulting in side effects so severe they require hospitalisation.
Additionally, the titration schedule allows clinicians to identify the optimal dose for each individual patient. Not everyone needs or tolerates the maximum dose. Some patients achieve excellent weight loss results at lower doses with minimal side effects. A good prescriber will work with the patient to find the "sweet spot"—the dose that provides meaningful appetite suppression and weight loss without causing intolerable side effects. This personalised approach is impossible with online platforms that simply send out pre-set doses without individualised assessment.
Support from medical professionals face-to-face (or at least over video-call) is also vital for the administration guidance. Injections are no laughing matter, they must be used and disposed of correctly to ensure absolute safety. While the injection pens for medications like WeGovy and Mounjaro are designed to be user-friendly and can be self-administered at home, proper training is still essential to ensure safe and effective use.
There are risks of using too much, using too little, or incorrect disposal, all of which pose real threats to patients and in the latter case, their families. Using too much medication—either by injecting more than prescribed or by injecting more frequently than weekly—can cause severe hypoglycemia (dangerously low blood sugar), extreme gastrointestinal distress, and other serious complications. Using too little—for example, by not injecting deeply enough or by injecting into areas with poor absorption—means the medication won't work effectively, leading to poor weight loss results and frustration. Incorrect injection technique can also cause bruising, pain, and injection site reactions.
Proper disposal of needles and injection pens is a serious safety concern. Used needles should never be thrown in regular rubbish bins where they could cause needlestick injuries to waste handlers or family members. They should be placed in a proper sharps container and disposed of according to local regulations. At Bodyline, we provide all our patients with sharps containers and clear instructions on safe disposal, and we can arrange for proper disposal of full containers.
Beyond the physical mechanics of injection, proper training includes education about where to inject (typically the abdomen, thigh, or upper arm), how to rotate injection sites to prevent lipodystrophy (changes in fat tissue at injection sites), how to store the medication (refrigerated but not frozen), how to check the medication for contamination or damage before use, and what to do if a dose is missed. These details matter for both safety and effectiveness, and they're often completely absent when medications are obtained through unregulated sources.
Bodyline's clinical lead and registered nurse manager Bernie Murphy explains the safe prescribing practises that govern the way we deal with patients seeking medical weight loss treatment from us. With decades of experience in medical weight management and a deep commitment to patient safety, Bernie and her team have developed rigorous protocols that ensure every patient receives the highest standard of care throughout their treatment journey.
"First and foremost, we're talking about our clinical team here. It is made up of doctors and highly experienced nurses who have their whole professional credentials on this so at the bottom of all our prescribing is about making sure that we are treating our clients with the utmost safety. Every member of our clinical team is a registered healthcare professional with the appropriate regulatory body—the General Medical Council for doctors and the Nursing and Midwifery Council for nurses. They maintain professional indemnity insurance, engage in continuous professional development, and are subject to professional standards and accountability. Their reputations, their registrations, and their livelihoods depend on providing safe, ethical care."
"There are strict comorbidities and contraindications that would rule many people out of using this medication, and they are put into place by the manufacturers, the MHRA that govern the licensing, and NICE which is the National Institute for Clinical Excellence. All these government bodies and corporations are a part of the licensing of the drug. These aren't arbitrary rules—they're based on extensive clinical trial data and post-marketing surveillance that has identified specific patient populations where the risks outweigh the benefits. When the MHRA licenses a medication, they specify exactly who it should be prescribed to, at what doses, and with what monitoring requirements. NICE then provides additional guidance on cost-effectiveness and appropriate use within the NHS. As prescribers, we are bound by these guidelines."
"If we as individual prescribers were to prescribe outside of those boundaries, we'd be putting the patient at risk. That means our clinical assessment of each individual is the basis of whether we will go ahead and prescribe. That can be quite a laborious process, involving contacting their GP and confirming their medical history, but it is all paramount for the individual's safety and the clinical reputation our staff. We don't take shortcuts. Every patient undergoes a comprehensive initial assessment that includes detailed medical history, current medications review, measurement of vital signs including blood pressure, calculation of BMI, discussion of weight loss goals and expectations, assessment for contraindications, and evaluation of readiness for lifestyle changes. In many cases, we contact the patient's GP to verify medical history and ensure we have complete information about any ongoing health conditions or medications."
This thorough approach means that occasionally we have to decline treatment to someone who desperately wants it but isn't a suitable candidate. This can be difficult, but it's the right thing to do. We'd rather disappoint someone by saying "no" than put them at risk by prescribing inappropriately. We also recognise that weight loss medication isn't the only option—for patients who aren't suitable for injections, we can often offer alternative treatments such as oral appetite suppressants like Phentermine or Diethylpropion, or we can provide structured support with diet and exercise without medication.
Our commitment to safe prescribing extends throughout the entire treatment journey, not just at the initial consultation. We maintain regular contact with our patients, monitoring their progress, adjusting doses as needed, providing ongoing education and support, and remaining alert for any signs of complications. We maintain detailed clinical records that document every consultation, every dose adjustment, and every concern or side effect reported. This level of care and documentation is what distinguishes legitimate medical practice from the unregulated "pill mills" operating online.
Faceless online pharmacies prescribe these medications based on a form that can be filled in with false information by anyone without being verified. The business model of many online pharmacies prioritises volume and convenience over safety. They process hundreds or thousands of orders per day with minimal human oversight, relying on algorithms and tick-box forms rather than clinical judgment. There's no video consultation, no measurement of vital signs, no verification of medical history, and often no qualified prescriber actually reviewing the application in any meaningful way.
This means that controlled prescription only medication can be given to those who are ineligible, with no supervision or monitoring to ensure that there are no adverse reactions. The consequences of this negligent approach are now becoming apparent as emergency departments across the UK report increasing numbers of patients presenting with complications from weight loss medications obtained online.
One terrifying instance of this is the case of a young girl being treated in an Accident and Emergency room, presenting with life-threatening symptoms after being prescribed and using WeGovy despite not being eligible. This case, reported by healthcare professionals to medical publications, highlights the very real dangers of inadequate prescribing safeguards.
An anonymous doctor spoke of treating this patient to The Chemist and Druggist, an online publication reporting on medication news, and said the young girl was not at all overweight but had gone online and paid £150 for a month's worth of injections. She had bought from a major British retailer who said they had relevant checks in place. This is particularly concerning because it wasn't a dodgy website operating from overseas—it was a well-known, supposedly reputable high street pharmacy chain. If even major retailers are failing to implement adequate safeguards, the problem is far more widespread than many realise.
A quote from the article reveals the scale of the problem:
'[The doctor] claimed that the incident is part of a growing pattern, adding that "in the last month or two, every time [they had] done a shift pretty much [they] had some patient who, to a lesser or greater degree, is having a complication from getting these weight loss drugs" - in many cases from an online pharmacy or private beauty clinic.
"Without fail, none of them would fit the criteria at all," they claimed, adding that another patient had "ended up going to intensive care" after obtaining weight loss drugs and presenting with pancreatitis.'
Intensive care. Pancreatitis. Complications. All real-life consequences of the alarmingly growing trend of weight loss drug misuse. Pancreatitis—inflammation of the pancreas—is a known potential side effect of GLP-1 medications, but the risk is significantly higher in patients who have certain pre-existing conditions or who are using inappropriately high doses. It causes severe abdominal pain, vomiting, and can be life-threatening if not treated promptly. The fact that patients are ending up in intensive care with this condition after obtaining medications online demonstrates a catastrophic failure of the safeguards that should be in place.
Other complications being seen in emergency departments include severe dehydration requiring intravenous fluids, electrolyte imbalances causing cardiac arrhythmias, acute kidney injury from dehydration, gallbladder problems including gallstones and cholecystitis, severe hypoglycemia causing confusion or loss of consciousness, and exacerbation of underlying eating disorders. These aren't minor inconveniences—they're serious medical emergencies that can have lasting health consequences or even be fatal.
The financial costs to the NHS of treating these preventable complications are also significant. Emergency department visits, hospital admissions, intensive care stays, and specialist consultations all represent healthcare resources being diverted to deal with problems that should never have occurred in the first place. This is healthcare spending that could be directed toward helping people who genuinely need these medications access them safely through properly supervised programmes.
Another severe real-life consequence of minimal checks and balances on online pharmacies and beauty providers is the alarming availability of these weight loss drugs for those who suffer with eating disorders. This represents perhaps the most ethically troubling aspect of unregulated access to weight loss medications, as individuals with eating disorders are among the most vulnerable patients and the most likely to experience serious harm from these drugs.
Eating disorders come in all shapes and sizes, and all BMIs, so even if a individual fits all other eligibility checks, any evidence of eating disorders should rule them out immediately. Anorexia nervosa, bulimia nervosa, binge eating disorder, and other specified feeding or eating disorders can affect people across the weight spectrum. Someone with a BMI of 32 might have binge eating disorder, while someone with a BMI of 22 might have atypical anorexia nervosa (all the psychological and behavioural features of anorexia but without being underweight). A simple BMI check is not sufficient to identify eating disorders—it requires careful clinical assessment and often specific screening questions.
Unfortunately, for those in the throes of it who are looking for a quick fix to weight loss, they may lie in order to obtain these drugs or go down unofficial routes like beauty clinics. The nature of eating disorders often involves secretive behaviour, denial of the problem, and intense drive to lose weight regardless of health consequences. Someone with active anorexia nervosa who is told by a legitimate medical provider that they're not eligible for weight loss medication may simply turn to unregulated sources instead. The ease of access through online platforms and social media removes one of the most important protective barriers for these vulnerable individuals.
According to BEAT, the UK's leading eating disorder charity, medications like semaglutide can be extremely dangerous as they can 'worsen harmful thoughts and behaviours for those unwell'. The appetite suppression and weight loss effects of these medications can reinforce and intensify the disordered eating patterns and distorted thinking that characterise eating disorders. For someone with anorexia, the medication might enable them to restrict their food intake even further, leading to dangerous malnutrition. For someone with bulimia, the nausea and vomiting side effects might be perceived as desirable and trigger more frequent purging behaviours.
When considering weight loss injections, having clear information and someone to turn to with questions matters. You should understand who is prescribing your treatment, how your suitability will be assessed and what support is available throughout your care.
Whether consultations take place online or in a clinic, the focus should be on your individual health needs. That includes discussing your medical history, current medications and relationship with food, alongside your weight management goals. You should also have the opportunity to ask about potential side effects, follow-up appointments and what happens if treatment is unsuitable.
At Bodyline Clinic, we believe that informed decisions start with an open conversation. Our clinical team can discuss your circumstances, assess whether medical weight management is appropriate and explain the options available to you.
Our approach combines individual assessment with ongoing support, helping you understand your treatment and raise any concerns as they arise.
To learn more about our medically supervised weight management programmes, contact Bodyline Clinic and speak to our team about your next steps.
BMI calculator
Enter your height and weight to work out your Body Mass Index in seconds.
Your BMI
Find out where you sit and what your options are
Your BMI
Our CQC-regulated clinical team will confirm your eligibility at consultation, in clinic or by video.
CQC regulated 4.8 on Trustpilot
If you'd like advice on your health and wellbeing, our team can talk you through the services we offer.
Explore our servicesWe'd recommend speaking to your GP, who can check everything is OK and offer the right support.
BMI ranges work differently for under 18s. Please speak to your GP for advice.
Please check your height and weight.
Contact us today
Find out more about how we can treat and support you to improve your health and wellbeing.
No-obligation advice from our CQC-regulated team, in clinic or by video.
